News for Regulus Therapeutics Inc. (RGLS)

Regulus offers strong return potential with an undervalued CVR tied to Farabursen approval

**media[637924]**

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of

PR NewswireSAN DIEGO, May 8, 2025 Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional

By the end of March 2025, Regulus Therapeutics (RGLS) reported holding $65.4 million in cash, cash equivalents, and short-term investments, ensuring financial s

PR NewswireNEW YORK, May 6, 2025 NEW YORK, May 6, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.

PR NewswireNEW YORK, May 1, 2025 NEW YORK, May 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

On May 1, 2025, Wells Fargo analyst Yanan Zhu announced a change in their rating for Regulus Therapeutics (RGLS). The rating has been downgraded from 'Overweigh

Strategic Acquisition: Novartis to acquire Regulus Therapeutics for $1.7 billion. Market Impact: Regulus shares surge over 130% post-announcement. An

Regulus Therapeutics (RGLS) experienced a downgrade from Oppenheimer, shifting from an Outperform to a Perform rating. This change occurred after Regulus entere

Regulus Therapeutics (RGLS) has seen its rating reduced from Outperform to Market Perform by Leerink. This downgrade follows the company's decision to enter int

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS acquisition.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday. The Dow traded down 0.47% to 40,335.51 while the NASDA...

U.S. stocks traded lower this morning, with the Dow Jones index falling over 600 points on Wednesday. Following the market opening Wednesday, the Dow traded do...

PR NewswireSAN DIEGO, April 30, 2025 Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in ca

California-based Regulus Therapeutics Inc. (RGLS), a clinical-stage biopharmaceutical company is up over 132 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero